|Day Low/High||159.78 / 162.93|
|52 Wk Low/High||133.65 / 173.65|
Let's review this Archegos drama and some lessons from this fickle market.
Here's my view on this space and where the money is to be made.
COVID numbers stopped improving a while ago, even with ever-improving rates of vaccination. Just what is going on here?
Let's set out the case for stocks -- and which kind -- and whether you might want to pay down other debt first.
You can listen to the haters on Twitter and Reddit, or you can see what I've been doing since 1979: trying to help the average Joe make some money.
Plus, the efficacy rate of the still-pending Novavax Covid-19 vaccine against variants of the virus give reason for pause.
How does this all end? I don't know that it does end.
A break in a key support level could precipitate further declines in the life sciences company's shares.
Smaller to mid-cap names have fared somewhat better than large cap tech, but make no mistake... there is a circle of life/death here.
Among other things, the president works to align Democratic senators to support his massive Covid relief bill.
Only 7% of Texas is vaccinated, or two million people. I don't want to mess with Texas or Texans until that number is higher.
Let's see what happens with these buy zones for both MSFT and JNJ.
Should we care about Australia's central bank taking overtly aggressive action to reign in the long end of their yield curve? Yes, we should.
The market's catalyst had everything to do with the virus... optimism that humankind might stuff that scourge back into Pandora's box.
I want you to think about how quickly the long end of the U.S. Treasury curve is moving.
No matter what you want to call it -- there are plenty of reasons to be bullish right now.
Plus, Thursday was a solid day for nearly all sectors of the market, though Peloton Interactive pulls back after posting results.
Let's not kid ourselves that there is any longer some kind of relationship between price and value. Or fact and truth.
Buyers of the healthcare giant's shares have been more aggressive as the company pushes to launch its own Covid-19 vaccine.
Wednesday afternoon the Fed's Federal Open Market Committee will publish the central bank's first official policy statement of 2021.
I can't say when the market's B-movie will matter, but here's what I can tell you based on the indicators.
The revenue and earnings beats are nice but that's not what really got me fired up.
Will the vaccine will be a game changer? The charts are giving indications that J&J is ready to run.
As a trader who at times takes short positions, I don't know whether to stand up and applaud this group or to fear them.
With few exceptions, there isn't a stock that could bring down this market.
GE remains a cash flow based story, but I see two negatives.
What can be done? Well for one, we are going to have to be creative. Jay, and Janet, I need you both paying attention here.